Week in Review: Suzhou Connect Biopharma In-Licenses Anti-Inflammatories from Arena
Suzhou Connect Biopharma, a new startup, in-licensed two series of anti-inflammatory compounds from Arena Pharma of San Diego; Transgene of France and China’s Tasly Pharma announced their JV will develop four of Transgene’s biotech immunotherapeutic candidates for China; SUMEC landed the exclusive right to distribute Aurora Imaging Technology’s breast imaging machines in China; Fenwal Holdings, a US company with a China JV, was bought by German medical equipment maker Fresenius for $1.1 billion; and chronic disease – diabetes, heart disease cancer – is placing a heavy burden on China’s healthcare system. More details…. Stock Symbols: (NSDQ: ARNA) (Euronext: TNG) (SHA: 600535) (FEX: FME) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here